AUTHORIZED AS A PHARMACEUTICAL COMPANY BY FRENCH REGULATORY AUTHORITIES (ANSM), CREAPHARM BIOSERVICES EXPANDS ITS SCOPE TO INCLUDE ADVANCED THERAPY MEDICINAL PRODUCTS
Reims Augut 31, 2003 – On the occasion of its third aniversary, the biobank which integrated CREAPHARM GROUP as CREAPHARM BIOSERVICES, got its Manufacturer’s Authorisation from the French National Agency for Medicines and Health Products (ANSM) on August 21th 2023.
A KEY LINK FOR THE CELL & GENE THERAPY STAKEHOLDERS
With a surge of 222 groundbreaking clinical trials launched in 2022 (1), the Cell & Gene Therapy (C>) sector continues to gain momentum. As a vital pillar in this transformative
landscape, CREAPHARM BIOSERVICES has achieved a remarkable milestone. The rigorous scrutiny conducted by the French Regulatory Authorities (ANSM) during file assessment has underscored CREAPHARM BIOSERVICES’ unwavering commitment and strict adherence to Good Manufacturing Practices (GMP). This achievement paves the way for CREAPHARM BIOSERVICES to extend its services, positioning itself as a key player in the storage, pharmaceutical packaging, QP-Release, and distribution of both investigational and market-approved Advanced Therapy Medicinal Products (ATMPs). To know more
